Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Int-H1-S6A F8 c-myc inhibitor

c-Myc inhibitor
BML-P605-0500 0.5 mg 196.00 USD
Do you need bulk/larger quantities?
H1 DNA-binding region of c-Myc containing Ser to Ala, and Phe to Ala substitutions (underlined) to confer an increase in its potency to inhibit c-Myc. The N-terminus of this peptide is the Int peptide sequence derived from the third Antennapedia homeodomain, to confer cell permeability. Control for this peptide is H1-S6A,F8A c-Myc inhibibitor peptide (Prod. No. BML-P606). Inhibited cloning efficiency of MCF-7 human breast cancer cells by 90% at 10 µM (IC50=5.9 µM). In MCF-7 cells, it inhibited cell growth and induced apoptosis. In addition, at 10 µM it strongly inhibited transcription of the c-Myc regulated genes ODC and p53. The non-cell-permeable control for this peptide is H1-S6A, F8A c-Myc inhibitor peptide which lacks the N-terminal internalization sequence.

Product Details

Purity:≥95% (HPLC)
Identity:Determined by MS.
Appearance:White to off-white powder.
Solubility:Soluble in water.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only

Product Literature References

Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence: L. Giorello, et al.; Cancer Res. 58, 3654 (1998), Abstract;
The third helix of the Antennapedia homeodomain translocates through biological membranes: D. Derossi, et al.; J. Biol. Chem. 270, 14255 (1995), Abstract;
Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR: L.J. Draeger, et al.; J. Biol. Chem. 269, 1785 (1994), Abstract;

Related Literature

Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Stem Cells
Stem Cells
Download as PDF

All new literature pieces

Recommend this page

Keep in touch

©2022 Enzo Life Sciences, Inc.,